© 2020 MJH Life Sciences™ and Cancer Network. All rights reserved.
Author | Gail M. Wilkes, MS, RNC
Articles
Vismodegib, a Hedgehog Pathway Inhibitor for Adults With Locally Advanced or Metastatic Basal Cell Carcinoma
August 27, 2012
Vismodegib is for the treatment of adults with metastatic basal cell carcinoma, or locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery, and who are not candidates for radiation.
Crizotinib, an ALK/MET Tyrosine Kinase Inhibitor for ALK-Positive NSCLC
May 10, 2012
Treatment of patients with locally advanced or metastatic non–small-cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.
Vemurafenib, a BRAF Inhibitor for Patients With Unresectable or Metastatic Melanoma and V600E-Mutated BRAF Protein
October 19, 2011
Vemurafenib is a protein kinase inhibitor that blocks the mutated gene protein BRAFV600E so that the cascade of messages that drive cell division and prevent apoptosis is stopped, resulting in tumor shrinkage.
Ipilimumab, a Human Monoclonal Antibody for Treatment of Unresectable or Metastatic Melanoma
July 11, 2011
Ipilimumab blocks cytotoxic T-lymphocyte antigen 4 (CTLA-4) and theoretically enables cytotoxic T cells to more effectively attack melanoma cells.